Statistics for Outlook Therapeutics (id:5399 OTLK)

Valuation metrics

Market cap

121.35M

Enterprise value

125.60M

Trailing P/E (ttm)

-1.05

Forward P/E

-2.00

PEG ratio

-2.00

Price/Sales (ttm)

Price/Book (mrq)

-1.40

Enterprise Value/Revenue

Enterprise Value/EBITDA

-2.05

Overview

Shares outstanding

23.66M

Float

13.53M

Shares short

3.23M

% Held by insiders

0.36%

% Held by institutions

0.36%

Average volume (10 days)

240.02K

Average volume (90 days)

Price summary

52-Week low

4.61

52-Week high

12.85

52-Week change

-82.90%

Beta

0.63

50-Day moving average

5.64

200-Day moving average

7.40

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

March 18th, 2019

Ex-dividend date

Last split factor

2:1

Last split date

March 14th, 2024

Financials

Fiscal year

Fiscal year ends

September 30th, 2023

Most recent quarter (mrq)

June 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

0.00%

Operational effectiveness

Return on assets

-83.69%

Return on equity

408.53%

Income statement

Revenue (ttm)

0.00

Revenue per share (ttm)

0.00

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-61,188,524.00

Net income to common (ttm)

-94,048,752.00

Diluted EPS (ttm)

-5.89

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

32.02M

Total cash per share (mrq)

1.35

Total debt (mrq)

32.72M

Total Debt/Equity (mrq)

-0.39

Current ratio (mrq)

107.20%

Book value per share (mrq)

-3.58

Cash flow

Cash flow statement

-64,553,276.00

Levered free cash flow (LFCF)

-43,587,760.00